Minov Jordan, Stoleski Sasho, Petrova Tatjana, Vasilevska Kristin, Mijakoski Dragan, Karadzinska-Bislimovska Jovanka
Institute for Occupational Health of Republic of Macedonia, Skopje, Republic of Macedonia.
Department of Pharmacy Practice, Chicago State University, Chicago, USA.
Open Access Maced J Med Sci. 2019 Dec 10;7(23):4030-4035. doi: 10.3889/oamjms.2019.697. eCollection 2019 Dec 15.
The failure of mucus clearance in bronchiectasis can be improved by chest physiotherapy or/and mucoactive agents.
To assess the effects of long-term use of carbocysteine on frequency and duration of exacerbations in patients with bronchiectasis.
We performed an observational, non-randomized, open study (a real-life study) including 64 patients with bronchiectasis divided into two groups, examined group (EG) and control group (CG). All participants were treated with appropriate treatment for the stable disease, but in the study, subjects of EG two capsules 375 mg carbocysteine three times a day was added over three months. Daily diary cards realised collection of data regarding the occurrence and duration of exacerbation in all study subjects.
Over the study period 43 exacerbations were documented, 17 in the EG and 26 in the CG, 10 (23.4%) of which required hospital treatment (four in the EG [23.5%] and six in the CG [23.1%]). A mean number of exacerbations over the study period was significantly lower in the EG (0.5 ± 0.1) as compared to their mean number in the CG (0.8 ± 0.2) (P = 0.0000). Mean duration of exacerbations expressed in days needed for complete resolution of symptoms or return of the symptoms to their baseline severity in the EG was significantly shorter than the mean duration of exacerbations in the CG (10.1 ± 2.6 vs 12.8 ± 2.1; P = 0.0000). The frequency of adverse effects, i.e. mild gastrointestinal manifestations and headache which did not require discontinuation of the treatment, in the EG during the study period was 15.6%.
Our findings indicated positive effects of carbocysteine regarding the frequency and duration of exacerbations, as well as its good tolerability in the patients with bronchiectasis.
支气管扩张症患者黏液清除功能障碍可通过胸部物理治疗或/和黏液促排剂得到改善。
评估长期使用羧甲司坦对支气管扩张症患者病情加重频率和持续时间的影响。
我们开展了一项观察性、非随机、开放性研究（一项真实生活研究），纳入64例支气管扩张症患者，分为试验组（EG）和对照组（CG）。所有参与者均接受了针对稳定期疾病的适当治疗，但在研究中，试验组受试者在三个月内每天额外服用375毫克羧甲司坦胶囊三次。通过每日日记卡收集所有研究对象病情加重的发生情况和持续时间的数据。
在研究期间记录到43次病情加重，试验组17次，对照组26次，其中10次（23.4%）需要住院治疗（试验组4次[23.5%]，对照组6次[23.1%]）。试验组研究期间病情加重的平均次数（0.5±0.1）显著低于对照组（0.8±0.2）（P=0.0000）。试验组症状完全缓解或症状恢复至基线严重程度所需天数表示的病情加重平均持续时间显著短于对照组（10.1±2.6天对12.8±2.1天；P=0.0000）。研究期间试验组不良反应（即无需停药的轻度胃肠道表现和头痛）的发生率为15.6%。
我们的研究结果表明羧甲司坦对支气管扩张症患者病情加重的频率和持续时间有积极影响且耐受性良好。
